Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of MK-0616 in adults with hypercholesterolemia
2021-005221-24Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypercholesterolemia comparing MK-0616 with Placebo (2 arms). Primary endpoint: Percent Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8. Started Dec 2021; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2021-005221-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005221-24.